ClinicalTrials.gg

Glomerulonephritis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 115 studies for Glomerulonephritis across more than 10 countries. 32 are recruiting or about to start. 40 of them are mainly about Glomerulonephritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 5 narrower conditions too, such as Lupus Nephritis: 899 studies, 333 open.

Status

Completed
49
Recruiting
26
Status unknown
16
Terminated
11
Active, not recruiting
6
Not yet recruiting
5

Phase

Phase 2
39
Phase 3
19
Phase 4
19
Phase 1
12

Where

United States
40
China
24
United Kingdom
21
Taiwan
15
Australia
14
Spain
14

Who develops what

Add Glomerulonephritis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 1 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Novartis and Swedish Orphan Biovitrum here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Immunosuppressive AgentsRecent, repeated
Evidence
  • NCT06342960 · Kyverna Therapeutics · Phase 2 · background · “Standard lymphodepletion regimen” · registered Mar 2024
  • NCT06047171 · Alentis Therapeutics AG · Phase 2 · live · background · “Immunosuppressive Agents” · registered Sep 2023
  • NCT05938725 · Kyverna Therapeutics · Phase 2 · background · “Standard lymphodepletion regimen” · registered Oct 2022
—23 studies

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 10 Aug 2027 est.zigakibart · Novartis · Phase 3 named, not the main aimNCT05852938 A Study of Zigakibart in Adults With IgA Nephropathy — primary endpoint: Change from baseline in eGFR · 383 enrolled
  • Nov 2027 est.TACI receptor-IgG Fc fragment fusion protein · Vera Therapeutics, Inc. · Phase 2 registry mapping onlyNCT06983028 Atacicept in Multiple Glomerular Diseases — primary endpoint: AE profile and results of routine clinical and laboratory tests · 250 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glomerulonephritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Endothelin receptor antagonists 2 open · Corticosteroids 2 open · SGLT2 inhibitors 2 open · Angiotensin receptor blockers (ARBs) 1 open

Coming up

10studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 26 Glomerulonephritis studies recruiting now, 15 (58%) set no upper age limit and 6 (23%) stop at 75 or younger. 6 (23%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (8%) take healthy volunteers.

Recruiting studies that take each age, of 26
AgeWomenMen
105 (19%)5 (19%)
1824 (92%)24 (92%)
3024 (92%)24 (92%)
4024 (92%)24 (92%)
5024 (92%)24 (92%)
6523 (88%)23 (88%)
7521 (81%)21 (81%)
8517 (65%)17 (65%)

Across all 115 studies, recruiting or not: 34% stop at 75 or younger and 19% at 65; 23% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 115. Browse all 115 → or search them.